Celyad SA is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Corporate operating segments. It derives majority of its revenues from Cardiology segment.
| Website: | www.celyad.com |
| Email: | investors@celyad.com |
| Main Phone: | +32 10394100 |
| Address: | Rue Edouard Belin 2 |
| City / Town: | Mont-Saint-Guibert |
| Country: | BEL |
| Postal Code: | 1435 |
| Exchange: | NSD |
| CEO: | Christian Homsy |
| Employees: | 77 |
| Last Price 21.05 | Change $ -2.36 | Change % -10.08 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask 23.75 | Ask Size 300.00 |
| Open 21.64 | High 21.64 | Low 20.89 | Prev Close 23.41 |
| Last Trade | Volume 4,794 | 52 Wk Hi 48.20 | 52 Wk Low 20.54 |
| Market Cap 251.4 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 11,942,344.00 | EPS (TTM) -7.39 | PE Ratio N/A | Exchange NSD |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 74 | 74 | 74 | 74 |
| Low Target Price Estimate | 49 | 74 | 74 | 49 |
| Mean Target Price Estimate | 61.5 | 74 | 74 | 61.5 |
| Standard Deviation | 17.68 | 0 | 0 | 17.68 |
| Date of Most Recent Estimate | 05/31/18 | 03/23/18 | 03/23/18 | 05/31/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 7 | 2018-05-23 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 58 | 2018-05-18 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 109 | 2018-05-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 8 | 2018-05-16 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 109 | 2018-05-16 |
| FWP | Free Writing Prospectus | 4 | 2018-05-16 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 37 | 2018-05-11 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 12 | 2018-05-03 |
| 20-F | Annual and transition report of foreign private issuers under sections 13 or 15(d) | 221 | 2018-04-06 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 17 | 2018-03-23 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 1 | 1 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
